West Pharmaceutical Services (WST) has been receiving positive attention from various investment and management groups. The company has been given an average rating of
Moderate Buy by analysts. Multiple entities, including
UBS, Wilmington Savings Fund Society FSB, Virtu Financial, Geode Capital Management, Quantinno Capital Management, and Two Sigma Advisers, have increased their holdings in WST. Nevertheless, some firms like Franklin Resources, Stifel Financial Corp, and Citigroup have lowered their stakes. The company's Q3 2024 Earnings highlighted
Strong Performance, and WST increased its
Fiscal Year 2024 Guidance. However, concerns have been raised regarding potential
industry headwinds and a possible sector downtrend, and the company faced a recent share unloading by Rep. Jared Moskowitz.
Critical developments include appointing a new director to the board and increasing the annual profit forecast due to the high demand for medical supplies. There is continued speculation about the health of the company in the face of
foreseen profit challenges and stiff competition.
West Pharmaceutical Services WST News Analytics from Thu, 15 Feb 2024 08:00:00 GMT to Sat, 14 Dec 2024 17:24:41 GMT -
Rating 6
- Innovation 3
- Information 4
- Rumor 1
